Withaferin A and its potential role in glioblastoma (GBM).

Jasdeep Dhami, Edwin Chang, Sanjiv S Gambhir

Journal: Journal of neuro-oncology 2017;131(2):201-211

PMID: 27837436

Abstract

Within the Ayurvedic medical tradition of India, Ashwagandha (Withania somnifera) is a well-known herb. A large number of withanolides have been isolated from both its roots and its leaves and many have been assessed for their pharmacological activities. Amongst them, Withaferin A is one of its most bioactive phytoconstituents. Due to the lactonal steroid's potential to modulate multiple oncogenic pathways, Withaferin A has gained much attention as a possible anti-neoplastic agent. This review focuses on the use of Withaferin A alone, or in combination with other treatments, as a newer option for therapy against the most aggressive variant of brain tumors, Glioblastoma. We survey the various studies that delineate Withaferin A's anticancer mechanisms, its toxicity profiles, its pharmacokinetics and pharmacodynamics and its immuno-modulating properties.

Address: Health Sciences Center, Texas Tech University, El Paso, TX, USA.; Department of Radiology, Molecular Imaging Program at Stanford and Canary Center at Stanford for Early Cancer Detection, Stanford University, Palo Alto, CA, USA.; Department of Radiology, Molecular Imaging Program at Stanford and Canary Center at Stanford for Early Cancer Detection, Stanford University, Palo Alto, CA, USA. [email protected].

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.